Phase 3 Readout~month
Phase 3 Topline: A Multicenter, Randomized, Double-Blind, Active-Controlled Phase Ⅲ Clinical Trial to Evaluate the Ef
- Company
- SINOVAC BIOTECH LTD (SVA)
- Drug
- high-risk
- Indication
- Tetanus
Other upcoming events for SVA
Phase 3 ReadoutPhase 3 Topline: A Randomized, Double-Blind, Active Comparator-Controlled Phase Ⅲ Trial to Evaluate the Immunogenicit
Phase 3 ReadoutPhase 3 Topline: A Randomized, Double-Blind, Active Comparator-Controlled Phase Ⅲ Trial to Evaluate the Immunogenicit
Phase 3 ReadoutPhase 3 Topline: A Phase III, Randomized, Double-blind, Active Controlled Clinical Trial to Evaluate the Immunogenici
Phase 3 ReadoutPhase 3 Topline: A Phase III, Randomized, Double-blind, Active Controlled Clinical Trial to Evaluate the Immunogenici
Phase 3 ReadoutPhase 3 Topline: A Randomized, Double-Blind, Active Comparator-Controlled Phase Ⅲ Trial to Evaluate the Immunogenicit
Track this catalyst and more
Get real-time alerts, AI-powered analysis, and full catalyst coverage.